Spartan COVID-19 System: Evaluation of Clinical Sample Collection

NCT ID: NCT04473248

Last Updated: 2020-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-28

Study Completion Date

2020-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the efficacy of various sample collection methods for use with the Spartan COVID-19 System. It will compare the results from the Spartan COVID-19 System with results that are obtained using a predicate lab-based COVID-19 test that uses a nasopharyngeal swab sample. The goal is to determine which sample collection methods are most effective in capturing SARS-CoV-2 virus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Once the subject is recruited,two nasopharyngeal swabs using the standard method will be taken from the patient. Additionally, two nasal swab samples will be taken using the Spartan COVID-19 swabs with an adjusted tip. All samples will be analyzed using the Spartan COVID-19 System.

The lab-based predicate test will be taken at the same time, with results reported back to Spartan to be compared with results obtained from the Spartan COVID-19 System.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Each Patient enrolle dint he study will experience the same modes of sample collection and sample analysis.
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants
The results of the Spartan COVID-19 System tests will not be shared with the participant or the lab, but the lab results will be shared with Spartan once analysis of the Spartan System samples is complete.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Method 1- Nasopharyngeal Swab in transfer liquid

A nasopharyngeal swab will inoculate a proprietary solution which will be transferred to the Spartan COVID-19 System for analysis

Group Type EXPERIMENTAL

Spartan COVID-19 System

Intervention Type DEVICE

PCR analysis of patient samples using the Spartan COVID-19 System

Method 2- Dipping of specialized swab in VTM

A nasopharyngeal swab will inoculate VTM solution. A modified traditional Spartan Swab will be dipped into the inoculated VTM solution and then transferred to the Spartan COVID-19 System for analysis.

Group Type EXPERIMENTAL

Spartan COVID-19 System

Intervention Type DEVICE

PCR analysis of patient samples using the Spartan COVID-19 System

Method 3: Direct input of VTM

Using the VTM from Method 2, pipette 10uL of VTM, inoculated with sample, into the Spartan COVID-19 System for analysis.

Group Type EXPERIMENTAL

Spartan COVID-19 System

Intervention Type DEVICE

PCR analysis of patient samples using the Spartan COVID-19 System

Method 4: Collection of nasal sample.

Using a modified tip of the Spartan swab, a nasal sample will be taken from the patient and directly placed into the Spartan COVID-19 System for analysis.

Group Type EXPERIMENTAL

Spartan COVID-19 System

Intervention Type DEVICE

PCR analysis of patient samples using the Spartan COVID-19 System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spartan COVID-19 System

PCR analysis of patient samples using the Spartan COVID-19 System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* must have tested positive for COVID-19 via the existing nucleic acid testing method.

Exclusion Criteria

\-
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Humber River Hospital

OTHER

Sponsor Role collaborator

The Ottawa Hospital

OTHER

Sponsor Role collaborator

Spartan Bioscience Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tara Linseman, MSc

Role: STUDY_DIRECTOR

Spartan Bioscience Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Humber River Hospital

North York, Ontario, Canada

Site Status

The Univeristy of Ottawa Heart Institute

Ottawa, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VNV-00552

Identifier Type: -

Identifier Source: org_study_id